AbbVie (NYSE: ABBV) announces that it has completed its acquisition of Aliada Therapeutics. With the completion of the acquisition, Aliada is now a part of AbbVie. Aliada’s lead investigational asset is ALIA-1758, an anti-pyroglutamate amyloid beta (3pE-Aβ) antibody, which is in development for the treatment of patients with Alzheimer’s disease and is currently in a Phase 1 clinical trial. ALIA-1758 utilizes a novel blood-brain barrier (BBB)-crossing technology that enhances delivery of targeted drugs into the central nervous system (CNS).
Read the full article: AbbVie Completes Acquisition of Aliada Therapeutics //
Source: https://www.prnewswire.com/news-releases/abbvie-completes-acquisition-of-aliada-therapeutics-302329026.html